ABSTRACTS EDITED BY THOMAS J. LIESEGANG, MD
●
Efficacy of eye patching for traumatic corneal abrasions: A controlled clinical trial. Le Sage N,* Verreault R, Rochette L. Ann Emerg Med 2001;28:129 –134.
phoid hyperplasias. Mannami T, Yoshino T, Oshima K, Takase S, Kondo E, Ohara N, Nakagawa H, Ohtsuki H, Harada M, Akagi T.* Mod Pathol 2001;14:641– 649.
T
I
HE AUTHORS EVALUATED THE EFFICACY OF EYE PATCH-
ing in the treatment of traumatic corneal abrasions in terms of time to healing and reduction in pain and discomfort. One hundred and sixty-three patients presenting at the emergency department of a large universityaffiliated hospital with traumatic corneal abrasions were included in this single blind prospective controlled trial. Eligible patients were assigned to one of two treatment regimens: topical antibiotic ointment and occlusive patch over the affected eye (n ⫽ 82) or topical antibiotic ointment four times a day without an occlusive patch (n ⫽ 81). Patients were reexamined every 24 hours until corneal healing occurred. Healing evaluation was performed by the emergency physician, using a slit lamp with fluorescein staining, without knowledge of the patient’s assignment to a treatment group. The degree of discomfort was assessed at each visit by using a visual analog scale. Both treatment groups were similar regarding size of the corneal lesions, delay from trauma to first visit, presence of foreign body or siderosis, initial degree of discomfort, and presence of specific symptoms (i.e., irritation, foreign body sensation, photophobia, redness, and pain). In the patched group, cumulative incidences of healing were 51%, 78%, and 92% after one, two, and three days, respectively, compared with 60%, 83%, and 88% in the nonpatched group. In the patched group, symptoms of initial discomfort decreased by 4.8, 4.1, and 5.5 cm after one, two, and three days, respectively, compared with 3.3, 5.1, and 6.5 cm in the nonpatched group. The authors conclude that eye patching does not appear to be beneficial in the treatment of traumatic corneal abrasions compared with topical antibiotic ointment.—Thomas J. Liesegang
*De´partment d’urgence, Centre hospitalier Affilie´ de l’Universite´ Laval, Hopital L’Enfant-Je´sus, 1401, 18ie´me rue, Que´bec, Que´bec, Canada G1J IZ4. E-mail:
[email protected]
●
Clinical, histopathological, and immunogenetic analysis of ocular adnexal lymphoproliferative disorders: Characterization of MALT lymphoma and reactive lym806
©
2001 BY
N THIS STUDY, 76 PATIENTS WITH OCULAR ADNEXAL
lymphoid proliferations were evaluated. The 76 cases included 52 lymphomas (43 primary and 9 secondary), 22 reactive lymphoid hyperplasias, and 2 borderline cases. The diagnoses were based on morphology and immunohistologic characteristics. Clonality was detected by polymerase chain reaction (PCR), and immunoglobulin heavychain variable region (VH) genes were sequenced in 10 cases of mucosa-associated lymphoid tissue (MALT) lymphoma. MALT lymphoma constituted 86% (37 cases) of the primary lymphomas. MALT lymphomas were more indolent, more rarely disseminated, and had a lower death rate than the other primary lymphomas. Two patients exhibited coexistence of MALT and diffuse large B-cell lymphoma. The average age of patients with RLH was 5.5 years younger than that of those with MALT lymphoma. One of the cases of RLH later progressed to malignant lymphoma. B-cell clonality was detected by PCR in 57%, 55%, and 0% of primary lymphomas, MALT lymphomas, and RLHs, respectively. Sequencing of VH genes revealed that the VH3 family was the most commonly expressed germ line VH family (70%) and the DP-63, DP-54, and DP-47 genes were frequently found in the MALT lymphomas examined. PCR analysis was useful for differentiation between MALT lymphoma and RLH. Sequence analysis of VH genes showed that an autoimmune mechanism might be involved in the lymphomagenesis of ocular adnexal MALT lymphoma.—Hans E. Grossniklaus
*Department of Pathology, Okayama University Medical School, 2-5-1 Shikata-cho, Okayama, 700-8558, Japan. E-mail:
[email protected]. okayama-u.ac.jp
●
Prognostic factors in uveal melanoma. Singh AD,* Shields CL, Shields JA. Melanoma Res 2001;11:255–263.
T
HE ANNUAL INCIDENCE OF UVEAL MELANOMA IS AP-
proximately six cases per million per year. Approximately 40% of patients with posterior uveal melanoma develop metastatic melanoma to the liver within 10 years
ELSEVIER SCIENCE INC. ALL
RIGHTS RESERVED.
0002-9394/01/$20.00